Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?
- 20 September 2006
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 100 (1) , 1-11
- https://doi.org/10.1007/s10549-005-9075-x
Abstract
Paradoxical induction of apoptosis by estrogen has been described previously for estrogen-deprived and antiestrogen-resistant breast cancer cells. In this study we analyzed the possible interrelations between cell sensitization to estrogen apoptotic action and cell ability to (anti)estrogen-independent growth. Using tamoxifen-resistant sublines derived from the parent MCF-7 breast cancer cells by long-term tamoxifen treatment we demonstrated that resistant cells are characterized by increased level of EGF receptor and unexpected increase of VEGF receptor 2 (Flk-1/KDR) and its specific ligand, VEGF-A. The importance of the VEGF signaling in the autocrine regulation of cell growth was indicated by the ability of VEGF inhibitor, soluble fragment of Flt-1/Fc chimera, to suppress the phosphorylation of MAP kinases as well as to inhibit the estrogen-independent growth of MCF-7 cells. Sensitization of tamoxifen-resistant cells to estrogen-induced apoptosis required the additional continuous cultivation in steroid-depleted medium and did not depend on the activity of both EGF and VEGF pathways. Finally, we showed that treatment of the cells with 17β-estradiol (10−9 M) resulted in a marked increase in p53 level both in the resistant cells undergoing apoptosis and in the parent MCF-7 cells insensitive to apoptotic estrogen action. These data provide an important support for the existence of a disbalance between pro- and anti-apoptotiс machinery in the resistant breast cancer cells that forms independently of the acquired ability to estrogen-independent growth.Keywords
This publication has 30 references indexed in Scilit:
- Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1Molecular and Cellular Endocrinology, 2005
- Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cellsEndocrine-Related Cancer, 2004
- Evolution of breast cancer treatments: current options and quality-of-life considerationsEuropean Journal of Oncology Nursing, 2004
- Apoptotic Action of 17 -Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In VivoJNCI Journal of the National Cancer Institute, 2003
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene, 2003
- Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen DeprivationJournal of Biological Chemistry, 2003
- Down-regulation of p21 WAF1/CIP1 or p27 Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cellsProceedings of the National Academy of Sciences, 2000
- Expression of VEGF in routinely fixed material using a new monoclonalThe Journal of Pathology, 1998
- Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein KinaseScience, 1995
- ?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancerBreast Cancer Research and Treatment, 1995